{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:46:10Z","timestamp":1787010370191,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    A 47-year-old man presented with a grade II well-differentiated metastatic neuroendocrine tumor originating from the pancreas. Initial treatment included trans-arterial embolization, long-acting octreotide, followed by chemotherapy. Despite these interventions, progressive disease was noted, prompting evaluation for peptide receptor radionuclide therapy using\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTATATE PET\/CT; however, this imaging revealed nonavid lesions. Subsequently, a\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-FAPI-46 scan was conducted, demonstrating favorable uptake in both the liver metastases and the primary tumor, leading to the administration of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-2286 therapy. This case highlights the potential of FAPI as a novel imaging and therapeutic strategy in the management of neuroendocrine tumors.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006204","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:01:44Z","timestamp":1765206104000},"page":"e340-e341","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["FAP-targeted Radio-ligand Therapy in Pancreatic Neuroendocrine Tumor"],"prefix":"10.1097","volume":"51","author":[{"given":"Farid","family":"Jafari Zarrin Ghabaei","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center"},{"name":"Student Research Committee, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Saber Tanha","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"},{"name":"Student Research Committee, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Raeisi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"},{"name":"Student Research Committee, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3507-2077","authenticated-orcid":false,"given":"Somaye","family":"Barashki","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2967\/jnumed.124.267982","article-title":"Dual somatostatin receptor\/ 18 F-FDG PET\/CT imaging in patients with well-differentiated, grade 2 and 3 gastroenteropancreatic neuroendocrine tumors","volume":"65","author":"Metser","year":"2024","journal-title":"J Nucl Med"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/RLU.0000000000000533","article-title":"A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET\/CT uptake by primary site\u2013dependent neuroendocrine tumor metastasis","volume":"39","author":"Kunikowska","year":"2014","journal-title":"Clin Nucl Med"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2967\/jnumed.118.214361","article-title":"Fibroblast-activating protein: targeting the roots of the tumor microenvironment","volume":"59","author":"Siveke","year":"2018","journal-title":"J Nucl Med"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RLU.0000000000003937","article-title":"The combined interpretation of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"47","author":"Hayes","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/RLU.0000000000005231","article-title":"Heterogeneous uptake of 68Ga-DOTATATE and 18F-FDG in initial diagnosed neuroendocrine tumors patients","volume":"49","author":"Zhou","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R6-20260401","first-page":"1899","article-title":"[18 F]FDG and [68 Ga]Ga-FAPI-04\u2013directed imaging for outcome prediction in patients with high-grade neuroendocrine neoplasms","volume":"65","author":"Michalski","year":"2024","journal-title":"J Nucl Med"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/RLU.0000000000003763","article-title":"Comparison of 18F-FDG, 68Ga-FAPI, and 68Ga-DOTATATE PET\/CT in a patient with pancreatic neuroendocrine tumor","volume":"46","author":"Cheng","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1055\/a-1521-8604","article-title":"Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET\/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours","volume":"60","author":"Kreppel","year":"2021","journal-title":"Nuklearmed- Nucl Med"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1186\/s12885-024-13153-1","article-title":"Head-to-head study of [18F]FAPI-04 PET\/CT and [18F]FDG PET\/CT for non-invasive assessment of liver cancer and its immunohistochemical markers","volume":"24","author":"Liang","year":"2024","journal-title":"BMC Cancer"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/RLU.0000000000003490","article-title":"68Ga-FAPI PET\/CT versus 68Ga-DOTATATE PET\/CT in the evaluation of a patient with neuroendocrine tumor","volume":"46","author":"K\u00f6mek","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1097\/RLU.0000000000004888","article-title":"177Lu-DOTATATE (Lutathera) tTherapy in 68Ga-DOTATATE PET\/CT-negative liver metastases of a neuroendocrine tumor","volume":"48","author":"Ventura","year":"2023","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:00:53Z","timestamp":1775077253000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006204"}},"subtitle":["A Potential Alternative to PRRT"],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006204","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"2025-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}